In Vitro Diagnostics - APAC

APAC

Highlights

The In Vitro Diagnostics market market in APAC is anticipated to witness significant growth, with projected revenue of US$22.53bn by 2024.
This market is expected to maintain a steady annual growth rate (CAGR 2024-2029) of 3.83%, leading to a market volume of US$27.19bn by 2029.
In terms of global comparison, the United States is projected to generate the highest revenue, reaching US$30.10bn in 2024.
The use of In Vitro Diagnostics in APAC is rapidly increasing, driven by advancements in technology and a growing demand for personalized healthcare solutions.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The In Vitro Diagnostics market in APAC is witnessing steady growth due to several factors.

Customer preferences: Customers in the APAC region have shown a growing preference for In Vitro Diagnostics products. This can be attributed to the increasing awareness about the importance of early disease detection and prevention. Customers are becoming more proactive in managing their health and are seeking diagnostic tests that can provide accurate and timely results. Additionally, the rising prevalence of chronic diseases in the region has also led to a higher demand for In Vitro Diagnostics products.

Trends in the market: One of the key trends in the In Vitro Diagnostics market in APAC is the adoption of advanced technologies. Market players are investing in research and development to develop innovative diagnostic tests that are more accurate, efficient, and cost-effective. For example, there is a growing demand for molecular diagnostics, which can detect diseases at the genetic level and provide personalized treatment options. Another trend is the increasing use of point-of-care testing, which allows for rapid diagnosis and treatment decisions at the patient's bedside.

Local special circumstances: The APAC region consists of diverse countries with unique healthcare systems and regulatory frameworks. This poses challenges for market players in terms of product registration and market entry. However, many countries in the region are taking steps to streamline regulations and improve access to healthcare, which is creating new opportunities for In Vitro Diagnostics companies. Additionally, the region's large population and increasing healthcare expenditure are also contributing to market growth.

Underlying macroeconomic factors: Several macroeconomic factors are driving the growth of the In Vitro Diagnostics market in APAC. The region's improving healthcare infrastructure and increasing investments in healthcare are creating a conducive environment for market expansion. Additionally, the rising disposable income and changing demographics are also influencing market dynamics. As the population ages, the demand for diagnostic tests is expected to increase, leading to further market growth. In conclusion, the In Vitro Diagnostics market in APAC is experiencing steady growth due to customer preferences for early disease detection, the adoption of advanced technologies, local special circumstances, and underlying macroeconomic factors. Market players in the region have the opportunity to capitalize on these trends and expand their presence in this growing market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

Explore more high-quality data on related topic

Medical technology industry - statistics & facts

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.